尽管血动力学目标较高,但血管活性使用较高,与急性心肌梗塞相关心脏性休克死亡率较高有关
Jorge A Ortega-Hernández1, Héctor González-Pacheco1, Diego Araiza-Garaygordobil1
1Coronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez, Tlalpan, Ciudad De México, México.
Frontiers in cardiovascular medicine
|February 28, 2025
概括
在急性心肌梗塞与心脏性休克 (AMI-CS) 中使用两种以上的血管活性药物显著增加了住院死亡率. 达到血液动力学目标并不能减轻这种增加的风险,强调需要仔细选择药物.
科学领域:
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心脏性休克 (CS) 是急性心肌梗塞 (AMI) 的危及生命的并发症,死亡率高.
- 有限的研究存在于最佳选择和使用血管活性剂在管理AMI-CS.
- 本研究研究了血管活性药物治疗方案对AMI-CS.患者住院治疗结果的影响.
研究的目的:
- 研究使用的血管活性药物数量与AMI-CS患者住院死亡率之间的关联.
- 分析血管活性药物选择对血液动力学参数和生存的影响.
- 评估实现血动力学目标是否会影响接受多种血管活性药物的患者的死亡风险.
主要方法:
- 对309名患有AMI-CS且经过肺动脉导管治疗的患者 (2006-2021) 的回顾性分析.
- 根据使用的血管活性药物的数量 (0-1,2或>2) 将患者分为组.
- 用临床数据,24小时血液动力学监测和后勤回归来评估结果和死亡概率.
主要成果:
- 接受>2种血管活性药物的患者在医院内死亡率显著增加 (调整后的危险比率[HRadj=4.62).
- 达到血液动力学目标并没有降低接受>2血管活性剂 (HRadj = 7.18) 的患者的死亡率.
- 血压素和levosimendan与更高的早期死亡率有关,尽管这种效应随着时间的推移而减弱.
结论:
- 在AMI-CS.中,血管活性药物的数量和住院死亡率之间存在显著的相关性.
- 使用超过2种血管活性剂与不良结果有关,无论血动力学目标的实现如何.
- 需要进一步的研究来探索最佳的血管活性策略和早期机械循环支持在AMI-CS.中的作用.
相关概念视频
01:24Blood Pressure Imbalances and Circulatory Shock
729
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
729
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
363
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
363
01:22Heart Failure Drugs: β-Blockers
306
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
306
01:26Heart Failure Drugs: Inotropic Agents
495
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
495
01:23Antihypertensive Drugs: Vasodilators
455
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
455
01:16Antianginal Drugs: Nitrates and β-Blockers
490
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
490